Clinical Data MSD, Eisai report setback in first-line kidney cancer trial PharmaphorumThe LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma. Clinical DataOncologyRead full story Post navigation Previous: Gilead, Arcus tumble again in TIGIT, triggering 2 trial cullsNext: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
